TR200101082T2 - Compositions to improve awareness or perception. - Google Patents

Compositions to improve awareness or perception.

Info

Publication number
TR200101082T2
TR200101082T2 TR2001/01082T TR200101082T TR200101082T2 TR 200101082 T2 TR200101082 T2 TR 200101082T2 TR 2001/01082 T TR2001/01082 T TR 2001/01082T TR 200101082 T TR200101082 T TR 200101082T TR 200101082 T2 TR200101082 T2 TR 200101082T2
Authority
TR
Turkey
Prior art keywords
active ingredient
perception
alzheimer
disease
compositions
Prior art date
Application number
TR2001/01082T
Other languages
Turkish (tr)
Inventor
Leonce Irma De Nijs Paul
Louis Julien Parys Wim
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of TR200101082T2 publication Critical patent/TR200101082T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Bu bulus, bir tasiyici ve her biri, psikoz veya Alzheimer hastaligi veya iliskili demanslardan müzdarip hastalarda, terapötik açidan yararli bir etki meydana getiren bir miktarda olmak üzere, bir birinci aktif bilesen olarak tipik olmayan bir antipsikotik madde (I) ve ikinci aktif madde olarak bir asetilkolinesteraz inhibitörü (II) ihtiva eden farmasötik bilesimlerle ilgilidir. Sözü edilen yararli etki, Alzheimer hastaligi veya iliskili demanslardan müzdarip hastalarin bilinç islevleri üzerinde sinerjistik bir etki, veya söz konusu hastalarda algilama yeteneginin daha fazla kötülesmesinin önlenmesi, veya aktif maddelerden biri ile baglantili olumsuz etkilerin aktif bilesenlerden digeri tarafindan azaltilmasi seklinde olabilir.This invention is a carrier and a non-typical antipsychotic agent (I) as a first active ingredient (I) and a second active ingredient, each in an amount that produces a therapeutically beneficial effect in patients suffering from psychosis or Alzheimer's disease or related dementias. It relates to pharmaceutical compositions containing acetylcholinesterase inhibitor (II). Said beneficial effect may be a synergistic effect on consciousness functions of patients suffering from Alzheimer's disease or associated dementia, or a reduction in the detrimental ability of perception in such patients, or reduction of negative effects associated with one of the active ingredients by the other active ingredient.

TR2001/01082T 1998-10-16 1999-10-12 Compositions to improve awareness or perception. TR200101082T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98203454 1998-10-16

Publications (1)

Publication Number Publication Date
TR200101082T2 true TR200101082T2 (en) 2001-09-21

Family

ID=8234219

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01082T TR200101082T2 (en) 1998-10-16 1999-10-12 Compositions to improve awareness or perception.

Country Status (20)

Country Link
EP (1) EP1121131A2 (en)
JP (1) JP2002527469A (en)
KR (1) KR20010072878A (en)
CN (1) CN1367697A (en)
AU (1) AU6472799A (en)
BG (1) BG105302A (en)
BR (1) BR9914419A (en)
CA (1) CA2345767A1 (en)
EE (1) EE200100136A (en)
HK (1) HK1039745A1 (en)
HR (1) HRP20010262A2 (en)
HU (1) HUP0103781A3 (en)
ID (1) ID28441A (en)
IL (1) IL142588A0 (en)
NO (1) NO20011403L (en)
PL (1) PL348107A1 (en)
SK (1) SK4592001A3 (en)
TR (1) TR200101082T2 (en)
WO (1) WO2000023057A2 (en)
ZA (1) ZA200103081B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006201188B2 (en) * 2001-02-05 2007-11-15 Novartis Ag New use of iloperidone
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
BRPI0213564B8 (en) 2001-10-30 2021-05-25 Novartis Ag deposit and microparticle formulation comprising iloperidone and poly(d,l-lactide-co-glycolide) polymer, and process for preparing said microparticle
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
CA2552221A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
CN1922176A (en) * 2004-12-10 2007-02-28 艾博特公司 Condensed bicycle heterocycle substituted quinuclidine derivant
JP5379692B2 (en) 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
ATE554085T1 (en) 2006-11-30 2012-05-15 Probiodrug Ag NEW INHIBITORS OF GLUTAMINYL CYCLASE
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
MX2007008642A (en) * 2007-07-16 2009-02-25 World Trade Imp Export Wtie Ag Pharmaceutical composition comprising the combination of a benzisoxazolic derived agent and a reversible inhibiting agent of the cholinesterase enzyme prescribed for the control and treatment of psychotic disorders and dementias.
AU2011215870B2 (en) 2010-02-09 2016-01-28 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
JP5688745B2 (en) 2010-03-10 2015-03-25 プロビオドルグ エージー Heterocyclic inhibitor of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
DK2968220T3 (en) 2013-03-15 2021-06-14 Agenebio Inc PROCEDURES AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DE69229781T2 (en) * 1991-05-14 2000-01-05 Ernir Snorrason TREATMENT OF FATIGUE SYNDROME WITH CHOLINESTERAS INHIBITORS
JP4640888B2 (en) * 1997-08-11 2011-03-02 ザ ユニヴァーシティー オブ サウス フロリダ Nicotine antagonists for neuropsychiatric disorders
EP2338482A3 (en) * 1998-04-14 2011-12-21 The General Hospital Corporation Methods for treating neuropsychiatric disorders

Also Published As

Publication number Publication date
BG105302A (en) 2001-11-30
BR9914419A (en) 2001-06-26
IL142588A0 (en) 2002-03-10
HK1039745A1 (en) 2002-05-10
NO20011403D0 (en) 2001-03-20
CN1367697A (en) 2002-09-04
HUP0103781A3 (en) 2003-09-29
EP1121131A2 (en) 2001-08-08
WO2000023057A2 (en) 2000-04-27
HUP0103781A2 (en) 2002-03-28
CA2345767A1 (en) 2000-04-27
AU6472799A (en) 2000-05-08
WO2000023057A3 (en) 2000-07-27
HRP20010262A2 (en) 2002-06-30
PL348107A1 (en) 2002-05-06
NO20011403L (en) 2001-03-20
JP2002527469A (en) 2002-08-27
ID28441A (en) 2001-05-24
EE200100136A (en) 2002-06-17
SK4592001A3 (en) 2001-12-03
KR20010072878A (en) 2001-07-31
ZA200103081B (en) 2002-07-12

Similar Documents

Publication Publication Date Title
TR200101082T2 (en) Compositions to improve awareness or perception.
DE59106756D1 (en) Novel anti-epileptics.
HUP0102521A2 (en) Antitumor agents comprising a stilbene derivative and a platinum coordination compound
TR200100172T2 (en) Biologically strengthened formulations containing eprosartan in oral solid dosage form
TR200103233T2 (en) New drug compositions on the basis of anticholinergic compounds and ß-mimetics.
TNSN00010A1 (en) CARBOXYARYL SUBSTITUTED DIPHENYLUREA AS RAF KINASE INHIBITORS.
ES2153975T3 (en) DERIVATIVES OF PIRIMIDONA WITH ANTIFUNGIC ACTIVITY.
TR200101895T2 (en) Treatment of sexual ailments.
ES2178036T3 (en) CYCLOSPORINE DERIVATIVES, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN YOU.
ATE211384T1 (en) USE OF ADENOSINE ANTAGONISTS TO PREVENT AND TREAT PANCREATITIS AND ULCERAS
ATE147981T1 (en) ADMINISTRATION OF LAMOTRIGINE FOR THE TREATMENT OF NEURO-AIDS
MX9701946A (en) Transporting ophthalmic solution.
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
TR199700878T1 (en) Pharmacological compositions containing inhibitors of monamine oxidase B.
DE59609926D1 (en) STABILIZED THYROID HORMONE DRUGS
TR200003736T2 (en) Prevention of changes due to anxiety states or depression
TR200200449T2 (en) Active ingredient combination containing clonidine
HUP0303935A2 (en) Ketolide antibacterial compounds
SE8103369L (en) ANTIPERSPIRANT COMPOSITION CONTAINING AN ALUMINUM CHLORIDE AND AN ALUMINUM ZIRCONIUM HYDROXYCHLORIDE AS ACTIVE INGREDIENTS AND SET TO INHIBIT PERSPIRATION
NZ319138A (en) Composition containing cytochrome complex III and fenazaquin for combatting parasitic fungi
TR199700858A2 (en) Pharmaceutical compositions for the treatment of Alzheimer's disease.
MXPA03000606A (en) Benzofuran derivatives and their use as antibacterial agents.
DK0917460T3 (en) Cyclosporin formulation
ATE309803T1 (en) SPHINGOMYELINASE INHIBITORS AS ACTIVE INGREDIENTS WITH ANTIAPOPTOTIC AND ANTISEPTIC EFFECTS
DK0593520T3 (en) Compounds containing steroids content and their use in the treatment of glaucoma